A Phase 2/3, Randomized, Parallel-Group, Placebo-Controlled, Double-Blind Study to Evaluate the Efficacy and Safety of CT-P59 in Combination with Standard of Care in Hospitalized Patients with SARS-CoV-2 Infection (COVID19)
Latest Information Update: 11 May 2022
At a glance
- Drugs Regdanvimab (Primary)
- Indications COVID-19 respiratory infection
- Focus Registrational; Therapeutic Use
- Sponsors Celltrion
- 29 Aug 2021 This trial has been Discontinued in Italy according to European Clinical Trials Database record.
- 28 Dec 2020 New trial record